Advertisements


FDA approves Alnylam"s Onpattro as hATTR treatment

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 10th, 2018

FDA Approves $450,000-a-Year Treatment for Rare Disease

Patients who have hereditary transthyretin-mediated amyloidosis, or hATTR, will take the drug for the rest of their lives. Alnylam Phar.....»»

Category: europeSource: fortuneAug 11th, 2018

Alnylam confirms FDA approves Onpattro to treat polyneuropathy caused by hATTR

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 10th, 2018

Alnylam"s Onpattro approved by FDA to treat polyneuropathy caused by hATTR

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 10th, 2018

FDA approves first generic EpiPen in blow to Mylan

The EpiPen is getting competition. The Food and Drug Administration has approved what it described as the first official generic version of the EpiPen, a life-saving treatment for severe allergic reactions.....»»

Category: topSource: usatodayAug 16th, 2018

FDA approves first rival generic EpiPen, sending Teva shares up 6%

Shares of the U.S.-listed Teva Pharmaceutical Industries Ltd. surged 6.2% in extremely heavy Thursday afternoon trade after the company's generic version of the EpiPen allergic reaction treatment was approved by the Food and Drug Administ.....»»

Category: topSource: marketwatchAug 16th, 2018

FDA approves Teva"s generic EpiPen in blow to Mylan (TEVA, MYL)

Thomson Reuters   (Reuters) - The U.S. Food and Drug Administration on Thursday approved Teva Pharmaceutical Industries Ltd's generic version of Mylan NV's EpiPen for the emergency treatment of a.....»»

Category: topSource: businessinsiderAug 16th, 2018

Alnylam Pharmaceutical"s (ALNY) Conference Call to Discuss FDA Approval of ONPATTRO (Patisiran) - Slideshow

Alnylam Pharmaceutical"s (ALNY) Conference Call to Discuss FDA Approval of ONPATTRO (Patisiran) - Slideshow.....»»

Category: topSource: seekingalphaAug 13th, 2018

Alnylam (ALNY) Gets FDA Nod for First-Ever RNAi Therapeutic

Alnylam (ALNY) receives FDA approval for Onpattro to treat polyneuropathy of hereditary transthy.....»»

Category: dealsSource: nytAug 13th, 2018

Alnylam rare drug gets FDA approval, to cost $345,000 on average

Alnylam Pharmaceuticals Inc.'s rare disease drug Onpattro has been approved by the Food and Drug Administration, marking the first approval of a therapy that employs the RNA interference (RNAi) gene-silencing technique. Onpattro, also called patis.....»»

Category: topSource: marketwatchAug 11th, 2018

FDA approves Amicus" Galafold for treatment of patients with Fabry Disease

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 10th, 2018

Alnylam rare drug gets FDA approval, to cost $345,000 on oaverage

Alnylam Pharmaceuticals Inc.'s rare disease drug Onpattro has been approved by the Food and Drug Administration, marking the first approval of a therapy that employs the RNA interference (RNAi) gene-silencing technique. Onpattro, also called patis.....»»

Category: topSource: marketwatchAug 10th, 2018

Alnylam expects Germany to be first EU launch country for Onpattro

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 10th, 2018

Alnylam says Onpattro to be available from two specialty pharmacies

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 10th, 2018

Alnylam sees annual average list price before discounts of Onpattro of $450,000

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 10th, 2018

Alnylam shares halted on approval of "first-of-its kind" treatment

Alnylam Pharmaceuticals Inc. shares were halted in Friday trade before news that its rare dis.....»»

Category: topSource: marketwatchAug 10th, 2018

Alnylam announces alignment on value-based agreements for Onpattro

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 10th, 2018

Alnylam tells Bloomberg will work with FDA to get broader claims for Onpattro

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 10th, 2018

Gilead says CNDA approves Genvoya for treatment of HIV-1 infection

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 6th, 2018

Bristol-Myers: EC approves Opdivo for treatment of adults with melanoma

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 31st, 2018

FDA approves Progenics" Azedra as first treatment for rare adrenal tumors

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 30th, 2018